+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Non-Small Cell Lung Cancer Clinical Trial Pipeline Highlights - 2019

  • ID: 4773882
  • Report
  • March 2019
  • Region: Global
  • Fore Pharma
1 of 2
This report, Non-Small Cell Lung Cancer Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Non-Small Cell Lung Cancer market. It covers emerging therapies for Non-Small Cell Lung Cancer in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Non-Small Cell Lung Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Non-Small Cell Lung Cancer pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Non-Small Cell Lung Cancer pipeline products by the company.

Short-term Launch Highlights:

Find out which Non-Small Cell Lung Cancer pipeline products will be launched in the US and Ex-US till 2024.

Summary:
  • Non-Small Cell Lung Cancer phase 3 clinical trial pipeline products
  • Non-Small Cell Lung Cancer phase 2 clinical trial pipeline products
  • Non-Small Cell Lung Cancer phase 1 clinical trial pipeline products
  • Non-Small Cell Lung Cancer preclinical research pipeline products
  • Non-Small Cell Lung Cancer discovery stage pipeline products
  • Non-Small Cell Lung Cancer pipeline products short-term launch highlights

Note: Please allow up to 48 hours for delivery after order is placed.
Please Note: This report will be delivered within 2 business days of ordering.
Note: Product cover images may vary from those shown
2 of 2
1. Non-Small Cell Lung Cancer Pipeline by Stages

2. Non-Small Cell Lung Cancer Phase 3 Clinical Trial Insights

3. Non-Small Cell Lung Cancer Phase 2 Clinical Trial Insights

4. Non-Small Cell Lung Cancer Phase 1 Clinical Trial Insights

5. Non-Small Cell Lung Cancer Preclinical Research Insights

6. Non-Small Cell Lung Cancer Discovery Stage Insights

7. Appendix

8. Research Methodology

List of Tables:
Table 1: Non-Small Cell Lung Cancer Phase 3 Clinical Trials, 2019
Table 2: Non-Small Cell Lung Cancer Phase 2 Clinical Trials, 2019
Table 3: Non-Small Cell Lung Cancer Phase 1 Clinical Trials, 2019
Table 4: Non-Small Cell Lung Cancer Preclinical Research, 2019
Table 5: Non-Small Cell Lung Cancer Discovery Stage, 2019

List of Figures:
Figure 1:: Non-Small Cell Lung Cancer Pipeline Molecules by Clinical Trials Stage, 2019
Figure 2: Non-Small Cell Lung Cancer Phase 3 Clinical Trial Highlights, 2019
Figure 3: Non-Small Cell Lung Cancer Phase 2 Clinical Trial Highlights, 2019
Figure 4: Non-Small Cell Lung Cancer Phase 1 Clinical Trial Highlights, 2019
Figure 5: Non-Small Cell Lung Cancer Preclinical Research Highlights, 2019
Figure 6: Non-Small Cell Lung Cancer Discovery Stage Highlights, 2019
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll